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ABSTRACT
Peptide-loaded exosomes are promising cancer treatment vehicles; however, 
moderate T cell responses in human clinical trials indicate a need to further understand 
exosome-induced immunity. We previously demonstrated that antigen-loaded 
exosomes carry whole protein antigens and require B cells for inducing antigen-
specific T cells. Therefore, we investigated the relative importance of exosomal 
major histocompatibility complex (MHC) class I for the induction of antigen-specific 
T cell responses and tumour protection. We show that ovalbumin-loaded dendritic 
cell-derived exosomes from MHCI-/- mice induce antigen-specific T cells at the same 
magnitude as wild type exosomes. Furthermore, exosomes lacking MHC class I, as 
well as exosomes with both MHC class I and II mismatch, induced tumour infiltrating 
T cells and increased overall survival to the same extent as syngeneic exosomes in 
B16 melanoma. In conclusion, T cell responses are independent of exosomal MHC/
peptide complexes if whole antigen is present. This establishes the prospective of 
using impersonalised exosomes, and will greatly increase the feasibility of designing 
exosome-based vaccines or therapeutic approaches in humans.
INTRODUCTION
Exosomes are nano-sized membrane vesicles 
derived from the late endosomal compartment, capable 
of transferring proteins, lipids and RNA between cells 
[1, 2]. B cells and dendritic cells (DC) release exosomes 
expressing major histocompatibility complex (MHC) class 
I and II, as well as co-stimulatory molecules (CD80/86) 
and can induce peptide-specific T cell proliferation in 
an MHC dependent manner [3, 4]. Phase I clinical trials 
using DC-derived autologous exosomes as therapy have 
been shown to be safe but limited in inducing anti-tumour 
immune responses and antigen-specific T cells [5, 6].
The majority of studies investigating exosomes as a 
cancer vaccine or therapy have been focusing on loading 
exosomes with MHC class I or MHC class II restricted 
peptides to stimulate the immune system. However, we 
previously showed that only whole antigen-loaded exosomes, 
not peptide-loaded exosomes, are able to induce antigen-
specific CD4+ [7] and CD8+ [8] T cells in vivo. The stimulating 
effect could be potentiated by adding the natural killer 
T (NKT) cell ligand α-galactosylceramide (αGC) onto 
exosomes, which significantly reduced tumour growth [9].
Interestingly, exosomes from ovalbumin (OVA)-
loaded DCs carry full-length OVA as well as MHC/
peptide complexes [7]. Therefore, in theory, exosomes 
could stimulate T cells in the recipient by three different 
mechanisms; i) by direct activation through the exosomal 
MHC/peptide complex binding to T cells [3], ii) by 
recycling of the exosomal MHC onto the surface of antigen 
presenting cells [10], or iii) by exosome degradation and 
full processing by recipient antigen presenting cells, with 
peptide loading on endogenous MHC molecules. The latter 
would not require an MHC match between patient and 
exosome donor and would greatly increase the feasibility 
of vesicle-based therapeutics. Therefore, we investigated 
if MHC on exosomes is needed to trigger T cell responses 
to whole OVA-loaded DC-derived exosomes in vivo, and 
if an MHC mismatch on exosomes affected their function 
in lymphocyte activation and tumour eradication.
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Our results show that the exosome-induced immune 
response is independent of MHC class I expression on 
exosomes when delivery of whole antigen is accomplished. 
We demonstrate that exosomes lacking MHC class I induce 
OVA-specific CD8+ T cells and IFNγ expression to the same 
extent as wild type exosomes. In addition, treatment with 
allogeneic exosomes in a B16 melanoma model increased T 
cell infiltration, OVA specific antibody levels and survival, 
implying the possibility of using allogeneic exosomes as 
cancer immune therapies or vaccines.
RESULTS
Phenotype of B6 and MHCI-/- dendritic 
cell-derived exosomes
First, we wanted to eliminate the possibility that 
exosomes from MHC class I deficient (MHCI-/-) DCs 
display a different phenotype than their wild type (WT) 
counterpart. Therefore, we compared expression levels 
of MHC class I and other immune relevant molecules on 
C57Bl/6 bone marrow derived dendritic cells (BMDCs) 
and their exosomes from WT and MHC class I-/- mice. 
WT and MHC class I-/- BMDCs and their exosomes, 
hereafter referred to as B6 Exo-OVA and MHCI-/- Exo-
OVA respectively, exhibited MHC class II (I-A/I-E), 
CD9, CD80, CD81, CD86, and CD40 (Figure 1A, 1B) 
and CD11c, CD54 and CD63 (data not shown) at similar 
levels. However, CD1d expression was significantly 
reduced on MHC class I-/- BMDCs (Figure 1A) but not on 
their corresponding exosomes (Figure 1B). As expected, 
MHC class I (H2Kb) was not present on either MHC class 
I-/- BMDCs (Figure 1A) or on their exosomes (Figure 1B). 
Thus, we conclude that exosomes from MHCI-/- BMDCs 
have a similar set of costimulatory molecules as wild type 
exosomes. Furthermore, size distribution by nanoparticle 
tracking analysis (NTA) demonstrated that B6 Exo-OVA 
and MHCI-/- Exo-OVA had a diameter of 115 and 125 
nm, respectively. Exosomes could potentially carry the 
antigen on both their surface and internally. Therefore, 
OVA amounts were measured both by ELISA (Figure 1D) 
and western blot (Figure 1E). No differences in surface 
or internal OVA antigen levels were detected in B6 Exo-
OVA and MHCI-/- Exo-OVA. The exosome marker Alix 
was present at similar levels in all samples (Figure 1E).
Exosomes induce upregulation of MHC class II 
expression already one hour after injection
To test whether exosomes activate and target antigen 
presenting cells (APC) in the spleen, we injected PKH67 
stained Exo-OVA/αGC B6, MHCI-/- and BALB/c i.v. and 
analysed MHC class II expression on APCs in the spleen 
one hour after injection. The PKH67 signal was hardly 
detected, therefore only MHCII expression on recipient 
cells was analysed. DCs, inflammatory monocytes and 
macrophages upregulated MHCII expression already one 
hour after injection compared to a dye control (Figure 2). 
No difference in MHCII expression was seen on B cells. 
However, we have previously seen that Exo-OVA/αGC 
induce upregulation of CD69 on B cells already 24h after 
injection (unpublished data). We conclude that exosomes 
stimulate DCs, macrophages and B cells in the spleen 
early after injection.
Induction of CD8+ T cells is independent of 
exosomal MHC class I
The induction of antigen-specific T cells is a 
major goal in cancer immunotherapy. However, we have 
shown the efficacy of protein loaded over peptide-loaded 
exosomes in vivo. Therefore, we asked whether MHC class 
I molecules on exosomes are needed for the induction of 
antigen-specific T cells. We injected 40 μg of B6 Exo-
OVA, MHCI-/- Exo-OVA, free OVA (300 ng) or PBS i.v. 
into C57Bl/6 recipient mice and analysed the immune 
response 7 days after injection. The percentage of total 
splenic CD4+ T cells (Figure 3A) and CD8+ T cells (Figure 
3B) were equal in all treatment groups. OVA specific 
CD8+ T cells were significantly increased in B6 Exo-
OVA and MHCI-/- Exo-OVA injected groups compared 
to PBS and soluble OVA with no difference between 
the exosome injected groups (Figure 3C). In addition, 
in vitro CFSE proliferation assay with OT-I/Rag2-/- 
splenocytes (specific transgene that encodes a T cell 
receptor specific for SIINFEKL peptide) showed similar 
proliferation after stimulation with B6 Exo-OVA or MHCI-/- 
Exo-OVA (Supplementary Figure S1). Importantly, free 
OVA was not immunostimmulatory, demonstrating the 
adjuvant effect of the exosomes (Figure 3C). After ex vivo 
restimulation with the CD4-restricted peptide (OVA
323-339
), 
no significant differences in IFNγ production between the 
groups were observed (Figure 3D). In line with the flow 
cytometry data (Figure 3C), restimulation with SIINFEKL 
or OVA induced similar levels of IFNγ producing cells 
in B6 Exo-OVA or MHCI-/- Exo-OVA mice (Figure 3E, 
F). Taken together, these data support the hypothesis that 
MHC class I is not needed on the exosomes for inducing 
an antigen-specific CD8+ T cell response.
OVA/αGC exosomes enhance CD8+ T cell 
stimulation independently of MHC class I
Next, we investigated if potentiating the immune 
system by adding αGC onto exosomes would influence 
the independence of MHC class I molecules on exosomes. 
We have previously described that αGC associated with 
exosomes synergistically stimulates OVA specific CD4+ 
and CD8+ T cells and reduces tumour growth significantly, 
compared to only OVA-loaded exosomes [9]. Exosomes 
from B6 and MHCI-/- BMDCs induced similar levels of 
NKT cell proliferation (Figure 4A), indicating similar levels 
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Figure 1: Characterization of C57Bl/6 and MHCI-/- bone marrow derived dendritic cells (BMDC) and their exosomes. 
A. BMDC from B6 and MHCI-/- mice were analysed for surface markers by flow cytometry after 48 h of LPS activation. B. Exosomes 
from B6 and MHCI-/- BMDCs were bound to anti-CD9 beads and analysed for surface markers by flow cytometry. Data in A) and B) are 
presented as MFI ratios between specific antibody and corresponding isotype control. C. Size distribution of B6 and MHCI-/- exosomes 
measured by nanoparticle tracking analysis, data are shown as particle concentration as a mean of three different batches’ mode sizes 
for the two types. For flow cytometry data is presented as mean ± SEM (error bars) and a non-parametric Mann-Whitney test was used, 
n=4-7, * P < 0.05, ** P < 0.01, D. Surface OVA concentrations were measured by ELISA, data represents 4 independent batches of B6 
Exo-OVA and 5 independent batches of MHCI-/- Exo-OVA, data represents mean ± SEM, E. proteins were isolated from 3 independent 
batches of B6 and MHCI-/- exosomes and the same protein amount was analysed by western blot to compare the surface and intra 
exosomal amount of OVA.
Figure 2: MHC class II upregulation on DC, monocytes and macrophages 1 hour after exosome injection. 100 μg 
PKH67-labeled exosomes were injected i.v. into the tail vein of C57Bl/6 mice, as a control PKH67 alone was injected. A. MHC class 
II expression on CD11b- CD11c+ dendritic cells, B. MHC class II expression on CD11bhighCD11c- Ly6ChighLy6G-F4/80+ inflammatory 
monocytes, C. MHC class II expression on CD11bhighCD11c- Ly6ClowLy6G-F4/80+ macrophages, all data are shown as MFI ratios towards 
the dye control and as mean ± SEM. Data were analysed by Kruskal-Wallis with Dunn´s multiple comparisons, * P < 0.05.
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of αGC on the two exosome types. No differences between 
B6 and MHCI-/- exosome induced CD4+ and CD8+ T cell 
proliferation (Figure 4B,C) and percentages of OVA-specific 
CD8+ T cells (Figure 4D) were detected. Exosomes did not 
induce any changes in T follicular helper cells or percentages 
of marginal zone B cells, however they induced a slight 
increase in follicular B cells and germinal center B cells, but 
with no differences between B6 and MHCI-/- exosomes (data 
not shown). We further restimulated splenocytes with PMA/
Ionomycin/Brefeldin A and determined intracellular IFNγ 
expression. Both exosome types led to a similar increase 
in IFNγ+CD4+ (Figure 4E) and IFNγ+CD8+ (Figure 4F) 
T cells. ELISPOT assay showed that restimulation with 
SIINFEKL peptide (Figure 4H) and whole OVA (Figure 4I) 
induced comparable numbers of IFNγ expressing cells. 
No significant effect was observed when splenocytes were 
restimulated with CD4 peptide (Figure 4G). Importantly, B6 
Exo-OVA/αGC and MHCI-/- Exo-OVA/αGC exosomes did 
not show any differences in their capacity to induce IFNγ.
Cancer therapy is independent of exosomal 
MHC molecules
We wanted to investigate if exosomes lacking 
MHC class I are capable of diminishing tumour growth 
in a therapeutic tumour model. With the goal to increase 
feasibility of future cancer treatments in humans, we 
also tested allogeneic exosomes, i.e. with an MHC 
mismatch in both MHC class I and II (BALB/c Exo-
OVA/αGC). BALB/c exosomes expressed a similar 
phenotype compared to B6 and MHCI-/- and had 
similar OVA levels (Supplementary Figure S2A, S2B, 
S2C). Furthermore, they were able to induce in vitro 
proliferation of splenocytes from OTI/RAG2-/- in 
comparable levels to B6 and MHCI-/- exosomes (data 
not shown). B6 mice were injected s.c. with 200,000 
B16/OVA F1 melanoma cells followed by treatment 
with 40 μg of B6 Exo-OVA/αGC, MHCI-/- Exo-OVA/
αGC or BALB/c Exo-OVA/αGC four days after tumour 
inoculation. Tumour bearing mice showed enhanced 
tumour-infiltrating T cells and OVA specific T cells 
(Figure 5A and 5B, Supplementary Figure S3) and 
increased overall survival (Figure 5D) in all exosome 
treated groups. No significant difference was observed 
in tumour-infiltrating T cells between B6 Exo-OVA/
αGC, MHCI-/- Exo-OVA/αGC and BALB/c Exo-OVA/
αGC treated mice (Figure 5B). This suggests that MHC 
molecules on exosomes are not needed to trigger anti-
tumour immune responses in vivo. Furthermore, serum 
levels of OVA-specific antibodies were similar in all 
Figure 3: WT B6 and MHCI-/- exosomes induce similar percentages of OVA specific CD8+ T cells. 40 μg of B6 Exo-OVA, 
MHCI-/- Exo-OVA, soluble OVA (300 ng) or PBS were injected i.v. into B6 mice, which were sacrificed and analysed 7 days after injection. 
Percentage (%) of total A. CD4+ and B. CD8+ T cells C. OVA specific T cells (defined as live cells, B220-, TCRβ+, CD8+, pentamer+). IFNγ 
ELISPOT after ex vivo restimulation for 19 h with D. CD4 peptide OVA
323-339
 E. CD8 peptide SIINFEKL or F. whole OVA. Data are pooled 
from 3 independent experiments, n=14-15. Dots represent a single mouse and data are presented as mean ± SEM. Data were analysed by 
Kruskal-Wallis with Dunn´s multiple comparisons, * P < 0.05, ** P < 0.01, *** P < 0.001.
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treatment groups (Figure 5C), which indicates that 
also the B cell response is independent of MHC on 
exosomes.
To see whether a delayed model would separate the 
groups more, we reduced the number of injected tumour 
cells. However, also when injecting 30,000 B16/OVA 
melanoma cells, a significant increase in survival was 
seen in all treated groups, with the strongest effect seen 
after injecting BALB/c exosomes (Supplementary Figure 
S4A and S4B). Importantly, the MHC mismatch did not 
negatively influence the antigen-specific anti-tumour 
response compared to syngeneic or MHCI-/- exosomes.
DISCUSSION
The discovery of MHC/peptide complexes on 
exosomes led to the idea of using DC-derived exosomes to 
stimulate antigen-specific T cells in immunotherapy against 
cancer [11]. Indeed, peptide/MHC complexes on exosomes 
have been shown to be capable of stimulating T cells [10], 
Figure 4: Exosomes from WT B6 or MHCI-/- mice loaded with αGC and OVA induce similar immune responses. B6 mice 
were injected with 40 μg B6 Exo-OVA/αGC or MHCI-/- Exo-OVA/αGC and fed for 7 days with BrdU to assess in vivo proliferation. On day 7 
mice were sacrificed and splenocytes were analysed by flow cytometry. A. Splenic NKT cell proliferation (defined as live cells, B220-, TCRβ, 
NK1.1+, DimerX+, BrdU+) B. CD4+ T cell proliferation C. CD8+ T cell proliferation D. percentage (%) of OVA specific T cells (defined as 
live cells, B220-, TCRb+, CD8+, pentamer+). Intracellular flow cytometry analysis for IFNγ of E. CD4+ T cells and F. CD8+ T cells after 4 h 
restimulation with PMA/Ionomycin/Brefeldin A. Data are pooled from two independent experiments, n=8-10. IFNγ ELISPOT of mice injected 
with either B6 Exo-OVA or MHCI-/- Exo-OVA after ex vivo restimulation for 19 h with G. CD4 peptide OVA
323-339
, H. CD8 peptide SIINFEKL 
or I. whole OVA. Data are pooled from 4 independent experiments, n=16-18. Dots represent a single mouse and data are presented as mean ± 
SEM. Data were analysed by Kruskal-Wallis with Dunn´s multiple comparisons, * P < 0.05, ** P < 0.01, *** P < 0.001.
Oncotarget38712www.impactjournals.com/oncotarget
however, treatment with peptide-loaded exosomes has 
not been as efficient as anticipated [5, 6]. We have shown 
that whole antigen is carried by exosomes derived from 
antigen-pulsed DCs. Therefore, we questioned the relative 
importance of delivery of MHC/peptide complexes versus 
whole antigen in eliciting immune responses in vivo. In this 
study, we demonstrate that MHC molecules on exosomes 
are not crucial for inducing T cell responses or anti-tumour 
immunity, thereby negating the need for autologous DCs in 
exosome-based immunotherapy.
Here, we have used exosomes loaded with whole 
antigen and not only peptides. As exosomes and their 
cargo are easily taken up and processed by DCs [12], 
the antigenic peptides from the delivered antigen can be 
presented on MHC on the recipient DCs. Indeed, we show 
that exosomes activate DCs, monocytes and macrophages 
already one hour after injection (Figure 2). Furthermore, 
DCs have previously been shown to be important for a 
response to exosomes, as injection of OVA-pulsed DC-
derived exosomes induce CD8+ T cell responses in vivo 
only in the presence of CD11c expressing cells in the 
marginal zone [13, 14]. Interestingly, even adoptively 
transferred peptide-loaded DC need endogenous antigen-
presenting cells to stimulate T cells [15]. In addition, 
Morelli et al have shown that exosomal antigens can be 
cross-presented to CD8+ T cells by DCs [12].
The use of the patients’ own DC-derived exosomes 
in therapy is complicated, as it is not optimal to perform 
leukapheresis on already immunocompromised patients. 
Therefore, an evaluation of the possibility of using MHC 
mismatched exosomes is crucial for designing future 
exosome-based vaccines. In this study, we show that 
allogeneic and syngeneic exosomes stimulate similar 
percentages of tumour-infiltrating T cells in a B16 mouse 
melanoma model. This challenges the current dogma of 
the central role for MHC class I on exosomes to stimulate 
T cell responses. Our results demonstrate the potential of 
using non-personalised exosomes as cancer treatment, 
where allogeneic exosomes could be loaded with lysate 
from the patient’s own cancer cells. Whether other 
antigens can be loaded in exosomes as easily as OVA 
needs to be verified, but indeed, the antigen loading onto 
DC-derived exosomes could also be accomplished with 
hen egg white lysozyme (HEL) (our own unpublished 
data). It has been demonstrated that OVA uptake by DC 
is mainly mediated through the mannose receptor (MR), 
while cell associated-OVA is taken up MR independently 
[16]. However, different receptors have been shown to be 
Figure 5: OVA specific CD8+ T cell induction in B16 tumours by exosomes is independent of MHC molecules on 
exosomes. B6 mice were injected s.c. with 200,000 B16/OVA melanoma cells, tumour growth was monitored and mice were treated i.v. 
with 40 μg B6 Exo-OVA/αGC, MHCI-/- Exo-OVA/αGC or BALB/c Exo-OVA/αGC 4 days after tumour injection. Mice were sacrificed 
when the tumour reached a volume of 1,000 mm3. A. Representative flow cytometry plots (presented as CD45+, B220-, TCRb+, CD8+, 
pentamer+ cells) and B. analysis of OVA specific CD8+ T cells infiltrated into the tumour of all four treatment groups. Dots represent a single 
mouse and data are presented as mean ± SEM. Data were analysed by Kruskal-Wallis with Dunn´s multiple comparisons C. OVA-specific 
IgG antibodies in the sera of the sacrificed animals was determined by ELISA, D. Kaplan-Meier survival curve, data were analysed by 
Mantel-Cox test. Data represent 2 independent experiments, n=14-15, * P < 0.05, ** P < 0.01, *** P < 0.001.
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crucial for exosome binding and uptake which questions 
the necessity of MR receptors in our study [17].
One crucial point to consider if using allogeneic 
exosomes in cancer therapy is, whether the patient’s 
own DCs will be able to express the required amount 
of MHC on exosomes to induce a response. This might 
be overcome by the delivery of additional potentiating 
signals in or on the exosomes. Other immunostimulatory 
molecules like TLR ligands will induce MHC expression 
on the DCs and indeed have been shown to further 
potentiate the response to exosomes [18]. Previously, we 
published that co-delivery of the NKT cell ligand αGC 
and OVA on exosomes potentiate the immune response 
without inducing anergy after two injections and that these 
exosomes reduced tumour growth in the B16/OVA mouse 
melanoma model [9]. Here, we showed that the boosting 
effect of αGC also is independent of MHC.
Compared to allogeneic transplantation of organs 
where the antigens are constantly present, exosomes are 
quickly cleared from the blood in the marginal zone and 
are mainly taken up by macrophages [19] or DCs in the 
marginal zone [12]. It has previously been shown that 
DCs can present exosomal allo-peptides to T cells and 
induce T cell proliferation [12]. In cancer therapy this 
might even be beneficial. MHC specific antibodies binding 
after the second injection might lead to the formation of 
immune complexes which can induce higher antibody 
titers compared to the soluble antigen [20]. In addition, 
immune complexes induce more cross-presentation and 
subsequently more antigen-specific CD8+ T cells compared 
to soluble antigen alone [21]. The potent B cell stimulation 
and antigen-specific antibody production induced by both 
syngeneic and allogeneic exosomes further supports the 
use of allogeneic exosomes in vaccine approaches.
In summary, we have shown that MHC class I 
molecules on exosomes are not needed for eliciting an 
antigen-specific immune response if the whole antigen 
is present. Furthermore, we have demonstrated that even 
allogeneic exosomes are able to induce an anti-tumour 
immune response in vivo. We conclude that direct T cell 
stimulation by exosomes in vivo is negligible when whole 
antigen is present and that DC are taking up syngeneic and 
allogeneic antigen-loaded exosomes, process them and 
induce an antigen-specific T and B cell response (Figure 6B). 
This offers new possibilities in designing exosomal based 
cancer vaccines or treatments for other diseases, and hence 
provides new opportunities in using allogenic DC-derived 
exosomes in patients.
Figure 6: Possible mechanisms for T cell stimulation by antigen-loaded exosomes. Dendritic cell-derived exosomes carry 
MHC class I and II molecules on the surface and A. can stimulate T cells directly by binding to the T cell receptor. Direct stimulation of T 
cells requires syngeneic MHC (black) molecules on exosomes due to MHC restriction. B. Uptake of exosomes by antigen presenting cells 
can lead to their degradation and loading of exosomal peptides on the APC´s MHC molecules or C. the whole exosomal MHC/peptide 




C57Bl/6 (Taconic, Tornbjerg, Denmark), BALB/c 
(Taconic, Tornbjerg, Denmark) or (Charles River, 
Sulzfeld, Germany), OT-I/RAG2-/-, C57Bl/6 MHCI-/- 
(H2Kb and H2Db gene knockout) (kindly donated by 
Prof. Klas Kärre, Karolinska Institutet) were under 
specific pathogen-free conditions at the Karolinska 
Institutet´s animal facility. The Stockholm Regional Ethics 
Committee approved all experiments.
Bone marrow derived dendritic cells
Bone marrow derived dendritic cells (BMDCs) from 
6 to 8 weeks old female C57Bl/6, MHCI-/- on a C57Bl/6 
background, and BALB/c mice were cultured with GM-
CSF (Ag8653/X63 clone) and IL-4 (2 ng/ml) as previously 
described [7]. On day 6, 300 μg/ml Ovalbumin (Sigma) 
and where indicated, 100 ng/ml α-galacosylceramide 
(αGC) (KRN-7,000; Laradon Fine Chemicals) were added 
over night. On day 7, the antigens were washed away and 
the cells were cultured for 48 hours in media containing 
exosome-depleted FCS [22], GM-CSF, IL-4 and 30 ng/ml 
LPS (Sigma).
Exosome preparation from BMDC supernatant
Supernatant from BMDC culture (day 9) was 
centrifuged for 10 min at 300 g to remove cells, 
supernatant was transferred and centrifuged again for 30 
min at 3,000 g to remove cell debris and subsequently 
filtered through 0.22 μm pore sized filters (Nordic Biosite). 
Exosomes were isolated by ultracentrifugation for 2 hours 
at 100,000 g (Optima LXP-100, Beckmann Coulter). After 
one washing step with PBS the exosome enriched pellet 
was resuspended in a small volume of PBS, protein was 
measured by using DC protein assay (Biorad) according to 
the manufacturer’s protocol, subsequently exosomes were 
stored at -80 °C until further use.
Phenotypic analysis of exosomes by FACS
10 μl Sulfate-aldehyde latex microsphere beads 
(4 μm, 1.3 × 109 beads/ml, Invitrogen) were incubated 
with 10 μg anti-mouse CD9 antibody (KMC8, BD 
Pharmingen) for 30 min at RT. The volume was adjusted to 
500 μl and rotated over night at RT. After washing, beads 
were blocked with 100 mM glycine for 30 min followed 
by washing with 0.5% BSA/PBS. Exosomes were bound 
to anti-CD9 coated beads with a concentration of 2 μg 
exosomes per μl beads and phenotyped as described 
previously [7]. The exosome-bead complexes were 
analysed on a FACS Calibur (BD Bioscience) by FlowJo 
software (Tree Star Inc.).
Nanoparticle tracking analysis
The exosome size was measured by Nanoparticle 
tracking analysis (LM10HSB system, NanoSight, 
Amesbury, U.K.) equipped with a 405 nm laser running 
an NTA 3.0 analytical software package. Exosomes were 
diluted in PBS to reach a concentration of around 45 
particles/frame and within 2 × 108 to 8 × 108 particles/ml. 
Three independent exosome batches were run 5 times each 
for 60 sec with a camera level of 10 and screen gain of 2.6 
with a syringe pump speed of 50.
In vitro proliferation
Single cell suspension of spleen and lymph nodes 
from 6-8 week old OT-I/RAG2-/- mice was prepared by 
using 70 μm cell strainers (BD Biosciences). Red blood 
cells were lysed with ACK buffer (0.8% NH4Cl, 0.1% 
KHCO3, 0.1 mM EDTA [pH 7.3]) and washed with 
complete media (RPMI 1640 medium supplemented with 
200 mM L-glutamine, 100 IU/ml penicillin-streptomycin 
(Thermo Scientific), and 10% FCS (HyClone, Thermo 
Scientific) followed by a wash with PBS. Cells were stained 
with 5 μM CFSE according to the manufacturer’s protocol 
(Life Technologies) and incubated for 10 min at 37 °C. 
The reaction was stopped by using complete media and 
cells were plated out at 2 × 105 cells per well in a 96 well 
u-bottom plate. C57Bl/6, MHCI-/- or BALB/c exosomes 
were added in two different concentrations (1 μg or 10 μg 
per well), the OVA peptide SIINFEKL (2 μg/ml) was used 
as a positive control. The plate was incubated for 5 days at 
37 °C, 5% CO2. On day 5 cells were stained for CD8, TCRβ 
and CD44. Cells were analysed by a BD LSR Fortessa III 
(BD Bioscience) and FlowJo software (Tree Star Inc.).
Analysis of MHC class II expression in spleen 1h 
after exosome injection
Exosomes from C57Bl/6, MHCI-/- and BALB/c mice 
were stained with PKH67 (Sigma) as described before [23] 
and injected i.v. into C57Bl/6 mice. Mice were sacrificed 
one hour after injection and spleen was taken. Dye only 
was injected as a control. Dendritic cells were defined to be 
CD11b- CD11c+, inflammatory monocytes CD11bhighCD11c- 
Ly6ChighLy6G-F4/80+ and macrophages CD11bhighCD11c- 
Ly6ClowLy6G-F4/80+. Cells were analysed by a BD LSR 
Fortessa III (BD Bioscience) and FlowJo software. All used 
antibodies (1:400 dilution) are listed in the Supplementary 
Data (Supplementary Table S1).
In vivo proliferation
6-8 week old female C57Bl/6 mice were injected 
i.v. with 40 μg exosomes in 100 μl PBS or with the 
corresponding amount of soluble ovalbumin (OVA) 
(300 ng/mouse) on day 0. Mice were fed with 0.8 
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mg/ml 5-bromo-2´-deoxyuridine (BrdU, Sigma) in 
drinking water supplemented with 2.5% sugar for 7 
days. On day 7 mice were sacrificed and blood and 
spleens were collected. Single-cell suspensions from 
the splenocytes were prepared as previously described 
[7] and serum was collected from coagulated blood 
and frozen at -20°C. Splenocytes were stained and 
BrdU incorporation was measured according to the 
manufacturer´s protocol (BrdU staining kit, BD 
Bioscience). SIINFEKL positive CD8+ T cells were 
analysed by using the (PE)-labeled H-2Kb/SIINFEKL 
pentamer (ProImmune). NKT cells were analysed using 
the CD1d:Ig Recombinant Fusion Protein (DimerX; 
BD Bioscience). Cells were analysed by a BD LSR 
Fortessa III (BD Bioscience) and FlowJo software. 
All used antibodies (1:400 dilution) are listed in the 
Supplementary Data (Supplementary Table S1).
Intracellular cytokine staining
Single cell suspensions of splenocytes were 
stimulated ex vivo for 4 hours with 50 ng/ml Phorbol-12-
myristate 13-acetate (PMA), 500 ng/ml Ionomycin and 1 
μg/ml Brefeldin A (all from Sigma) in complete media. 
Intracellular cytokine staining for IFNγ (Biolegend) 
was performed by using transcription factor staining set 
(eBioscience), according to the manufacturer´s protocol.
Enzyme-linked immunospot assay
IFNγ specific ELISPOT was performed according 
to the manufacturer’s instructions (Mabtech). 200,000 
splenocytes per well were plated out on PVDF membrane 
plates (Millipore) followed by stimulation for 19 hours in 
37 °C with 2 μg/ml SIINFEKL, 2 μg/ml OVA
323-339
 peptide 
(Innovagen), 2 μg/ml Concanavalin A (Sigma), 2 μg/ml 
αGC, or culture media as a control.
Western blot
Total proteins were extracted from purified 
exosomes using RIPA buffer, sonication and vortexing. 
The exosomal proteins (10 μg) were run on a Mini-
Protean TGX precast gel (Any kD, Bio-Rad Laboratories, 
Hercules, CA, USA) and blotted to Trans-Blot Mini PVDF 
membranes using the Trans-Blot Turbo™ Transfer system 
(Bio-Rad). Blots were incubated with blocking buffer 
(5% non-fat milk/PBST) overnight at 4 °C. OVA was 
detected using an anti-OVA antibody (1:1,000; 0220-1682, 
AbD Serotec, Kidlington, UK), together with a donkey-
anti-rabbit secondary antibody (1:10,000; NA9340, 
GE Healthcare, Little Chalfont, UK). Alix was detected 
using an anti-Alix antibody (1:1000; 2171 (3A9), Cell 
Signaling technology, Danvers MA, US), together with a 
sheep-anti-mouse secondary antibody (1:2000; NA9310V, 
GE Healthcare, Little Chalfont, UK) and visualized 
by enhanced chemiluminescence (GE Healthcare), the 
ChemiDoc™ MP Imaging System and Image Lab™ 
software version 4.1 (both from Bio-Rad).
ELISA
The OVA concentrations on the surface of exosomes 
were determined by ELISA. 10 μg/ml exosomes were 
coated on ELISA plates over night at 4 °C. Mouse anti-
OVA antibody (Nordic Biosite, 1:10,000) was added and 
incubated for 2 hours at RT, followed by anti-mouse IgG 
HRP (Southern Biotech, 1:2,000) as secondary antibody 
incubated for 1 hour at RT, 3,3’,5,5’-Tetramethylbenzidine 
(TMB) substrate was used for detection according to the 
manufacturer´s protocol (Biolegend), the reaction was 
stopped by using 1 M H2SO4. The plates were read at 450 
nm using an ELISA reader (Perkin Elmer, Enspire 2300 
Multilabel reader). OVA specific IgG antibody levels were 
determined as described before [7].
B16/OVA melanoma tumour model
200,000 or 30,000 B16/OVA melanoma cells (F1) 
were injected s.c. in the right flank of C57Bl/6 mice. On 
day 4 mice were injected i.v. with either 100 μl PBS as 
a control or 40 μg of exosomes. Tumour growth was 
monitored and mice were sacrificed when the tumour 
volume reached 1,000 mm3. The tumour was cut into small 
pieces and incubated with Collagenase/Hyaluronidase 
(Roche) for 30 min at 37 °C. Subsequently, the tissue was 
passed through a 100 μm cell strainer and the single cell 
suspension was stained for FACS analysis using antibodies 
against CD45, TCR-β, CD8 (Supplementary Table S1) and 
PE-labeled H-2Kb/SIINFEKL pentamer (ProImmune).
Statistical analysis
Non-parametric data was analysed by Kruskal-
Wallis with Dunn´s correction. All analyses were done by 
using GraphPad software version 6.0 (GraphPad Inc.).
ACKNOWLEDGMENTS
The authors thank Kenth Andersson at the animal 
facility and Prof. Klas Kärre, Karolinska Institute, 
Stockholm for providing the MHCI-/- mice, Dr. E. Lord 
and Dr. J. Frelinger, University of Rochester, Rochester, 
for contributing the B16/OVA cell line and Hanna 
Sandberg, Stockholm, for the illustration.
FINANCIAL SUPPORT
This work was supported by grants from the Swedish 
Medical Research Council VR K2013-67X-15242-10-5, 
The Swedish Cancer Foundation 2013/867, The Cancer 
Research Foundations of Radiumhemmet 131082, The 
Stockholm County Council 20140405, The Swedish Heart-
Oncotarget38716www.impactjournals.com/oncotarget
Lung Foundation 20140497, 20140711, 20130551, The 
Centre for Allergy Research and the ChAMP consortium 
at the Karolinska Institute, the Hesselman Foundation, and 
the KID grant of the Karolinska Institute.
CONFLICTS OF INTEREST
S.G. has a patent on B-cell exosomes for immune 
therapy, US patent no. US 8932855 B2.
REFERENCES
1. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and 
Lotvall JO. Exosome-mediated transfer of mRNAs and 
microRNAs is a novel mechanism of genetic exchange 
between cells. Nature cell biology. 2007; 9:654-659.
2. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, 
Sena-Esteves M, Curry WT, Jr., Carter BS, Krichevsky 
AM and Breakefield XO. Glioblastoma microvesicles 
transport RNA and proteins that promote tumour growth 
and provide diagnostic biomarkers. Nature cell biology. 
2008; 10:1470-1476.
3. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, 
Harding CV, Melief CJ and Geuze HJ. B lymphocytes 
secrete antigen-presenting vesicles. The Journal of 
experimental medicine. 1996; 183:1161-1172.
4. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, 
Tenza D, Ricciardi-Castagnoli P, Raposo G and Amigorena 
S. Eradication of established murine tumors using a novel 
cell-free vaccine: dendritic cell-derived exosomes. Nature 
medicine. 1998; 4:594-600.
5. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay 
TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, 
Hsu DH, Le Pecq JB and Lyerly HK. A phase I study of 
dexosome immunotherapy in patients with advanced non-
small cell lung cancer. Journal of translational medicine. 
2005; 3:9.
6. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, 
Novault S, Flament C, Leboulaire C, Borg C, Amigorena 
S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh 
M, Piperno S, Robert C, et al. Vaccination of metastatic 
melanoma patients with autologous dendritic cell (DC) 
derived-exosomes: results of thefirst phase I clinical trial. 
Journal of translational medicine. 2005; 3:10.
7. Qazi KR, Gehrmann U, Domange Jordo E, Karlsson MC 
and Gabrielsson S. Antigen-loaded exosomes alone induce 
Th1-type memory through a B-cell-dependent mechanism. 
Blood. 2009; 113:2673-2683.
8. Naslund TI, Gehrmann U, Qazi KR, Karlsson MC and 
Gabrielsson S. Dendritic cell-derived exosomes need to 
activate both T and B cells to induce antitumor immunity. 
Journal of immunology. 2013; 190:2712-2719.
9. Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson 
MC, Naslund TI and Gabrielsson S. Synergistic induction 
of adaptive antitumor immunity by codelivery of antigen 
with alpha-galactosylceramide on exosomes. Cancer 
research. 2013; 73:3865-3876.
10. Andre F, Chaput N, Schartz NE, Flament C, Aubert 
N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu 
DH, Tursz T, Amigorena S, Angevin E and Zitvogel L. 
Exosomes as potent cell-free peptide-based vaccine. I. 
Dendritic cell-derived exosomes transfer functional MHC 
class I/peptide complexes to dendritic cells. Journal of 
immunology. 2004; 172:2126-2136.
11. Amigorena S. Anti-tumour immunotherapy using dendritic-
cell-derived exosomes. Research in immunology. 1998; 
149:661-662.
12. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, 
Stolz DB, Papworth GD, Zahorchak AF, Logar AJ, Wang Z, 
Watkins SC, Falo LD, Jr. and Thomson AW. Endocytosis, 
intracellular sorting, and processing of exosomes by 
dendritic cells. Blood. 2004; 104:3257-3266.
13. Hao S, Bai O, Yuan J, Qureshi M and Xiang J. Dendritic 
cell-derived exosomes stimulate stronger CD8+ CTL 
responses and antitumor immunity than tumor cell-derived 
exosomes. Cellular&molecular immunology. 2006; 
3:205-211.
14. Probst HC, Tschannen K, Odermatt B, Schwendener R, 
Zinkernagel RM and Van Den Broek M. Histological 
analysis of CD11c-DTR/GFP mice after in vivo depletion 
of dendritic cells. Clinical and experimental immunology. 
2005; 141:398-404.
15. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS and 
Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines 
requires antigen transfer to endogenous antigen presenting 
cells. PloS one. 2010; 5:e11144.
16. Burgdorf S, Lukacs-Kornek V and Kurts C. The mannose 
receptor mediates uptake of soluble but not of cell-
associated antigen for cross-presentation. Journal of 
immunology. 2006; 176:6770-6776.
17. Mulcahy LA, Pink RC and Carter DR. Routes and 
mechanisms of extracellular vesicle uptake. Journal of 
extracellular vesicles. 2014; 3.
18. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, 
Bonnaventure P, Aubert N, Bernard J, Lemonnier F, 
Merad M, Adema G, Adams M, Ferrantini M, Carpentier 
AF, Escudier B, Tursz T, et al. Exosomes as potent 
cell-free peptide-based vaccine. II. Exosomes in CpG 
adjuvants efficiently prime naive Tc1 lymphocytes 
leading to tumor rejection. Journal of immunology. 2004; 
172:2137-2146.
19. Saunderson SC, Dunn AC, Crocker PR and McLellan AD. 
CD169 mediates the capture of exosomes in spleen and 
lymph node. Blood. 2014; 123:208-216.
20. Hioe CE, Visciano ML, Kumar R, Liu J, Mack EA, Simon RE, 
Levy DN and Tuen M. The use of immune complex vaccines 
to enhance antibody responses against neutralizing epitopes on 
HIV-1 envelope gp120. Vaccine. 2009; 28:352-360.
Oncotarget38717www.impactjournals.com/oncotarget
21. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van 
Schip JJ, Sedlik C, Melief CJ, Verbeek JS and Ossendorp 
F. Antigen-antibody immune complexes empower dendritic 
cells to efficiently prime specific CD8+ CTL responses in 
vivo. Journal of immunology. 2002; 168:2240-2246.
22. Thery C, Amigorena S, Raposo G and Clayton A. Isolation 
and characterization of exosomes from cell culture 
supernatants and biological fluids. Current protocols in cell 
biology / editorial board, Juan S Bonifacino [et al]. 2006; 
Chapter 3:Unit 3 22.
23. Naslund TI, Paquin-Proulx D, Paredes PT, Vallhov H, 
Sandberg JK and Gabrielsson S. Exosomes from breast milk 
inhibit HIV-1 infection of dendritic cells and subsequent 
viral transfer to CD4+ T cells. Aids. 2014; 28:171-180.
